Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC) - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1007/s00213-008-1440-0. Epub 2008 Dec 20.

Affiliations

• PMID: 19099294
• DOI: 10.1007/s00213-008-1440-0

Randomized Controlled Trial

Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC)

Claudine C Hunault et al. Psychopharmacology (Berl). 2009 May.

Abstract

Rationale: Delta(9)-Tetrahydrocannabinol (THC) is the main active constituent of cannabis. In recent years, the average THC content of some cannabis cigarettes has increased up to approximately 60 mg per cigarette (20% THC cigarettes). Acute cognitive and psychomotor effects of THC among recreational users after smoking cannabis cigarettes containing such high doses are unknown.

Objectives: The objective of this study was to study the dose-effect relationship between the THC dose contained in cannabis cigarettes and cognitive and psychomotor effects for THC doses up to 69.4 mg (23%).

Materials and methods: This double-blind, placebo-controlled, randomised, four-way cross-over study included 24 non-daily male cannabis users (two to nine cannabis cigarettes per month). Participants smoked four cannabis cigarettes containing 0, 29.3, 49.1 and 69.4 mg THC on four exposure days.

Results: The THC dose in smoked cannabis was linearly associated with a slower response time in all tasks (simple reaction time, visuo-spatial selective attention, sustained attention, divided attention and short-term memory tasks) and motor control impairment in the motor control task. The number of errors increased significantly with increasing doses in the short-term memory and the sustained attention tasks. Some participants showed no impairment in motor control even at THC serum concentrations higher than 40 ng/mL. High feeling and drowsiness differed significantly between treatments.

Conclusions: Response time slowed down and motor control worsened, both linearly, with increasing THC doses. Consequently, cannabis with high THC concentrations may be a concern for public health and safety if cannabis smokers are unable to titrate to a high feeling corresponding to a desired plasma THC level.

Trial registration: ClinicalTrials.gov NCT00225407.

PubMed Disclaimer

Similar articles

• Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.
  Hunault CC, Mensinga TT, de Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, Leenders ME, Meulenbelt J. Hunault CC, et al. Psychopharmacology (Berl). 2008 Dec;201(2):171-81. doi: 10.1007/s00213-008-1260-2. Epub 2008 Aug 10. Psychopharmacology (Berl). 2008. PMID: 18695931 Clinical Trial.
• Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.
  Hunault CC, Böcker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J. Hunault CC, et al. Psychopharmacology (Berl). 2014 Dec;231(24):4723-33. doi: 10.1007/s00213-014-3630-2. Epub 2014 May 31. Psychopharmacology (Berl). 2014. PMID: 24879495 Clinical Trial.
• Cannabis with high δ9-THC contents affects perception and visual selective attention acutely: an event-related potential study.
  Böcker KB, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL. Böcker KB, et al. Pharmacol Biochem Behav. 2010 Jul;96(1):67-74. doi: 10.1016/j.pbb.2010.04.008. Epub 2010 Apr 24. Pharmacol Biochem Behav. 2010. PMID: 20417659 Clinical Trial.
• Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review.
  McCartney D, Arkell TR, Irwin C, McGregor IS. McCartney D, et al. Neurosci Biobehav Rev. 2021 Jul;126:175-193. doi: 10.1016/j.neubiorev.2021.01.003. Epub 2021 Jan 23. Neurosci Biobehav Rev. 2021. PMID: 33497784 Review.
• Biphasic effects of THC in memory and cognition.
  Calabrese EJ, Rubio-Casillas A. Calabrese EJ, et al. Eur J Clin Invest. 2018 May;48(5):e12920. doi: 10.1111/eci.12920. Epub 2018 Apr 2. Eur J Clin Invest. 2018. PMID: 29574698 Review.

Cited by

• Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels.
  King GR, Ernst T, Deng W, Stenger A, Gonzales RM, Nakama H, Chang L. King GR, et al. J Neurosci. 2011 Dec 7;31(49):17923-31. doi: 10.1523/JNEUROSCI.4148-11.2011. J Neurosci. 2011. PMID: 22159107 Free PMC article.
• Cognitive motor deficits in cannabis users.
  Prashad S, Filbey FM. Prashad S, et al. Curr Opin Behav Sci. 2017 Feb;13:1-7. doi: 10.1016/j.cobeha.2016.07.001. Curr Opin Behav Sci. 2017. PMID: 27482533 Free PMC article.
• Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol.
  Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA. Levin FR, et al. Drug Alcohol Depend. 2010 Jan 1;106(1):65-8. doi: 10.1016/j.drugalcdep.2009.07.021. Epub 2009 Sep 3. Drug Alcohol Depend. 2010. PMID: 19733018 Free PMC article. Clinical Trial.
• Neurophysiological and cognitive effects of smoked marijuana in frequent users.
  Hart CL, Ilan AB, Gevins A, Gunderson EW, Role K, Colley J, Foltin RW. Hart CL, et al. Pharmacol Biochem Behav. 2010 Sep;96(3):333-41. doi: 10.1016/j.pbb.2010.06.003. Epub 2010 Jun 18. Pharmacol Biochem Behav. 2010. PMID: 20600251 Free PMC article.
• Acute memory and psychotomimetic effects of cannabis and tobacco both 'joint' and individually: a placebo-controlled trial.
  Hindocha C, Freeman TP, Xia JX, Shaban NDC, Curran HV. Hindocha C, et al. Psychol Med. 2017 Nov;47(15):2708-2719. doi: 10.1017/S0033291717001222. Epub 2017 May 31. Psychol Med. 2017. PMID: 28558859 Free PMC article. Clinical Trial.

References

1. 1. Am J Public Health. 1999 Oct;89(10):1549-54 - PubMed
2. 1. J Clin Pharmacol. 1981 Aug-Sep;21(S1):143S-152S - PubMed
3. 1. Neuropsychopharmacology. 2008 Sep;33(10):2505-16 - PubMed
4. 1. Pharmacol Biochem Behav. 1998 Aug;60(4):777-84 - PubMed
5. 1. J Clin Psychiatry. 2003 Jan;64(1):20-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information